IONS – ionis pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
This 11-year-old has battled a rare disease for years — a breakthrough drug helped deliver relief [CNBC]
Ionis Pharmaceuticals (NASDAQ:IONS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $95.00 price target on the stock.
Ionis Pharmaceuticals (NASDAQ:IONS) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return [Yahoo! Finance]
Form 4 IONIS PHARMACEUTICALS For: Feb 02 Filed by: BENNETT C FRANK
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: Swayze Eric
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: Monia Brett P
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: O'NEIL PATRICK R.
Form 4 IONIS PHARMACEUTICALS For: Jan 29 Filed by: Schneider Eugene
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.